Grape King Bio Ltd (1707) Fair Value & Analysis

Healthcare · TW · Market cap 15.4B TWD

Analysis

Grape King Bio Ltd (1707) currently trades at 96.80 TWD, while our model-based Fair Value estimate is 172.71 TWD — implying the stock looks roughly 78.4% undervalued today. We read business quality at 80/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.

About the company

Grape King Bio Ltd, together with its subsidiaries, produces and sells pharmaceutical preparations, patent medicines, liquid tonics, drinks, and healthy food in Taiwan, China, and internationally. It operates through Multi-Level Marketing; Distributors; Original Design Manufacturer/Original Equipment Manufacturer; and Sales Channel segments. The company provides health products and supplements; and microbial fermentation for mushroom mycelium, probiotics, and enzymes. It also offers functional ingredients for intestinal care, immunity regulation, liver care, brain health, eye care, weight control, feminine health, sensual health care, and others. It serves pharmaceutical preparations, finished drugs, oral liquids, and beverages and health foods. The company was founded in 1969 and is headquartered in Taoyuan City, Taiwan.

Open the full interactive analysis →

Similar stocks

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.